Enrique Africa, individually and on behalf of all others similarly situated v. Jianpu Technology Inc.

District Court, S.D. New York·Decided May 19, 2021·No. 1:21-cv-01419·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ---------------------------------------------------------------------- X : ENRIQUE AFRICA, individually and on behalf of all : others similarly situated, : : Plaintiff, : 21-CV-1419 (JMF) : -v- : MEMORANDUM OPINION : AND ORDER JIANPU TECHNOLOGY INC. et al., : : Defendants. : : ---------------------------------------------------------------------- X JESSE M. FURMAN, United States District Judge: On February 17, 2021, Plaintiff Michael Guttentag filed a putative class action lawsuit on behalf of purchasers of Jianpu Technology Inc. (“Jianpu”) securities between May 29, 2018, and February 16, 2021. ECF No. 1 (“Compl.”), ¶ 1. The Complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. § 78a et seq., and Rule 10b-5, promulgated thereunder. The same day that Guttentag filed the Complaint, he also published notice of the lawsuit, in accordance with the Private Securities Litigation Reform Act (“PSLRA”), 15 U.S.C. § 78u-4(a)(3)(A). See ECF No. 6. On April 19, 2021, three motions were filed seeking appointment as lead plaintiff: one by Enrique Africa, ECF No. 15; one by Xiaoming Zhou, ECF No. 18; and one by Yan Qin Li, ECF No. 22. See 15 U.S.C. § 78u- 4(a)(3)(A) (providing that, “not later than 60 days after the date on which the notice is published, any member of the purported class may move the court to serve as lead plaintiff of the purported class”). On April 28, 2021, Li filed a notice of non-opposition to the competing lead plaintiff motions, ECF No. 29, and the Court later deemed Li’s motion withdrawn, ECF No. 33; see Plaut v. Goldman Sachs Grp., Inc., No. 18-CV-12084 (VSB), 2019 WL 4512774, at *3 (S.D.N.Y. Sept. 19, 2019) (denying motions of parties who filed notices of non-opposition). On May 13, 2021, the Court held a telephone conference on the record to address the remaining two competing lead plaintiff motions, after which the Court reserved judgment. The PSLRA directs courts to presume that the most adequate lead plaintiff is the movant

who, “in the determination of the court, has the largest financial interest in the relief sought by the class” and “otherwise satisfies the requirements of Rule 23 of the Federal Rules of Civil Procedure.” 15 U.S.C. § 78u-4(a)(3)(B)(iii). The statute does not define “largest financial interest,” but “courts have generally relied on” four factors identified in Lax v. First Merchants Acceptance Corp., Nos. 97-CV-2715 et al., 1997 WL 461036 (N.D. Ill. Aug. 11, 1997), commonly known as “the Lax factors,” Richman v. Goldman Sachs Grp., Inc., 274 F.R.D. 473, 475 (S.D.N.Y. 2011); see, e.g., Hom v. Vale, S.A., No. 15-CV-9539 (GHW), 2016 WL 880201, at *3 (S.D.N.Y. Mar. 7, 2016); Foley v. Transocean Ltd., 272 F.R.D. 126, 127-28 (S.D.N.Y. 2011). The four factors are: “(1) the number of shares purchased; (2) the number of net shares purchased; (3) total net funds expended by the plaintiffs during the class period; and (4) the

approximate losses suffered by the plaintiffs.” Richman, 274 F.R.D. at 475. Courts tend to treat the factors in ascending order of importance, with the size of the loss being the most important, but each factor is “only a proxy — and an imperfect one — for determining” which applicant for lead plaintiff has “the largest financial interest.” Id. at 476. Here, Zhou claims the largest loss — $48,944.84 — of any movant. See ECF No. 19, at 4. But Africa argues that the vast majority of Zhou’s losses should not be considered because, following the Supreme Court’s decision in Dura Pharmaceuticals, Inc. v. Broudo, 544 U.S. 336 (2005), courts have recognized that “[l]osses resulting from in-and-out transactions, which took place during the class period, but before the misconduct identified was ever revealed to the public are not to be included in loss calculations for purposes of selecting lead plaintiff.” ECF No. 32, at 4 (quoting Sallustro v. CannaVest Corp., 93 F. Supp. 3d 265, 273 (S.D.N.Y. 2015)). “When these transactions are removed from Zhou’s loss calculation,” Africa argues, “[Zhou’s] loss is only $2.61,” far less than Africa’s $2,307.37. Id. at 5. Zhou, in turn, notes that

“[n]umerous courts have held that partial corrective disclosures ‘enable a plaintiff to prove that it was harmed notwithstanding the fact it sold its shares prior to the complete disclosure of the alleged fraud,’” ECF No. 34 (“Zhou Reply”), at 2 n.1 (quoting Galmi v. Teva Pharm. Indus. Ltd., 302 F. Supp. 3d 485, 501 (D. Conn. 2017)), and that such “[p]artial corrective disclosures are alleged throughout the Complaint,” id. at 2 (footnote omitted). In the alternative, he also argues it is “not settled case law that being in-and-out automatically disqualified movants from lead plaintiff appointment.” Id. at 4 (citing Freudenberg v. E*Trade Fin. Corp., Nos. 07-CV-8358 (RWS) et al., 2008 WL 2876373, at *7 (S.D.N.Y. July 16, 2008)). At the May 13th conference, Africa argued that the partial corrective disclosures alleged in the Complaint have no bearing on Zhou’s losses because they occurred months before Zhou first purchased any Jianpu shares in

October 2020. The Court agrees with Africa. Although “the appropriateness of employing Dura analysis at the lead plaintiff stage” is not entirely settled, Cook v. Allergn PLC, No. 18-CV- 12089 (CM), 2019 WL 1510894, at *3 (S.D.N.Y. Mar. 21, 2019), the Court agrees with the weight of authority in this Circuit that it “would be abdicating its responsibility under the PSLRA if it were to ignore the issue of loss causation at the lead plaintiff appointment stage,” Sallustro, 93 F. Supp. 3d at 273 (cleaned up); accord Micholle v. Ophthotech Corp., Nos. 17- CV-210 (VSB) et al., 2018 WL 1307285, at *5 (S.D.N.Y. Mar. 13, 2018); In re Comverse Tech., Inc. Sec. Litig., No. 06-CV-1825 (NGG) (RER), 2007 WL 680779, at *5 (E.D.N.Y. Mar. 2, 2007), adhered to on reconsideration, 2008 WL 820015 (E.D.N.Y. Mar. 25, 2008). Thus, generally speaking, “[a]ny losses incurred based on ‘in-and-out’ trades — where an investor buys stock and sells it during the class period but before any disclosures — should not be considered.” Micholle, 2018 WL 1307285, at *5 (citing Topping v. Deloitte Touche Tohmatsu CPA, 95 F. Supp. 3d 607, 618 (S.D.N.Y. 2015)).1 That said, “some courts have been reluctant to

apply Dura at the appointment-of-lead-plaintiff stage if a case involves multiple disclosures and the analysis of recoverable losses is murky and lacks sufficient evidence.” City of Sunrise Firefighter’s Pension Fund v. Citigroup Inc., Nos. 20-CV-9132 (AJN) et al., 2021 WL 396343, at *3 (S.D.N.Y. Feb. 4, 2021); see also Plaut, 2019 WL 4512774, at *4 (“Under the circumstances presented here, in which the complaint alleges multiple partial disclosures over the course of the Class Period, courts have been reluctant to apply a Dura-based approach to calculating losses.”).

Free access — add to your briefcase to read the full text and ask questions with AI

Enrique Africa, individually and on behalf of all others similarly situated v. Jianpu Technology Inc., (S.D.N.Y. 2021).

Enrique Africa, individually and on behalf of all others similarly situated v. Jianpu Technology Inc. (Enrique Africa, individually and on behalf of all others similarly situated v. Jianpu Technology Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
Sallustro v. CannaVest Corp.
93 F. Supp. 3d 265 (S.D. New York, 2015)
Topping v. Deloitte Touche Tohmatsu CPA, Ltd.
95 F. Supp. 3d 607 (S.D. New York, 2015)
Galmi v. Teva Pharm. Indus. Ltd.
302 F. Supp. 3d 485 (D. Connecticut, 2017)
Lentell v. Merrill Lynch & Co.
396 F.3d 161 (Second Circuit, 2005)
Foley v. Transocean Ltd.
272 F.R.D. 126 (S.D. New York, 2011)
Richman v. Goldman Sachs Group, Inc.
274 F.R.D. 473 (S.D. New York, 2011)
In re Gentiva Securities Litigation
281 F.R.D. 108 (E.D. New York, 2012)